Could third time be the charm for Advair copycats? Novartis’ Sandoz aims to find out

16th June 2017 Uncategorised 0

The FDA has already struck down two generics of GlaxoSmithKline respiratory blockbuster Advair. But Novartis’ Sandoz is hoping its version can be the one to turn the tide.

More: Could third time be the charm for Advair copycats? Novartis’ Sandoz aims to find out
Source: fierce